SEC Form 4 · accession 0001179110-18-012090
ENDOCYTE INC · ECYT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Beth Taylor
Officer — VP Finance & Chief Acctg Offcr
Period of report
Oct 5, 2018
Accepted (ET)
Oct 9, 2018 · 2:20 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001235007
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Oct 5, 2018 | S | 7,022 | $15.5635 | D | 56,341 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents the sale of 7,022 shares in a multiple transactions, ranging in price from $15.1300 to $15.9200, resulting in a weighted-average sale price per share of $15.5635. The 7,022 shares were sold to cover taxes, commissions and fees associated with the October 4, 2018 settlement of 15,000 restricted stock units in the form of Company common stock on a one-for-one basis. The shares were sold by Merrill Lynch pursuant to a written plan as specified in Rule 10b5-1(c) of the Securities Exchange Act of 1934 adopted by the reporting person on July 30, 2018.